TOKYO, April 28, 2017 (GLOBE NEWSWIRE) – FRONTEO Healthcare, Inc. (“FRONTEO Healthcare”), a subsidiary of FRONTEO, Inc. (“FRONTEO”) (NASDAQ: FTEO) (TSE: 2158) which provides medical data analysis solutions using the artificial intelligence (“AI”) engine “KIBIT” and the Japanese Foundation for Cancer Research (“JFCR”) began research and development of a precision medicine system against cancer that can use advanced genome analysis technology and AI. Through this research, FRONTEO Healthcare and JFCR aim to develop precision cancer medicine that will provide the best treatment for every cancer patient based on genetic testing.

The JFCR established the Cancer Precision Medicine Center in October 2016. Using cutting-edge technologies for genome analysis on cancer cells and tissues, it aims to develop next-generation cancer diagnostics that can lead to better treatments. FRONTEO Healthcare also announced in October 2016 that it has started development of its Precision Cancer Medicine AI System (“CPM-AI System.”)

Through their joint research activity, JFCR and FRONTEO Healthcare will seek to develop a system that helps physicians make clinical decisions based on genetic information from cancer cells. The system will consist of an AI researching academic papers that can help find the most appropriate treatment for each individual based on the result of the genetic test.

The Cancer Precision Medicine Center will seek to develop a system that integrates and analyzes information about cancer patients, such as cancer genome data, using the latest methods, including clinical sequencing, which performs comprehensive mutation research. genetic in cancer cells and fluid biopsy, which detects genetic mutations in blood and other body fluids. One of the CPM-AI systems that FRONTEO Healthcare will develop through the “Diagnosis Support System” is a system that analyzes academic papers and medical data using the knowledge of cancer experts from all fields. The system will make suggestions when doctors decide on the course of treatment based on the test results.

In addition to the diagnostic support system, FRONTEO Healthcare will develop an “informed consent (IC) support system”, in which FRONTEO’s AI technology will maximize the effectiveness of the IC by supplementing the explanations according to the level of understanding of patients and their families. FRONTEO Healthcare plans to complete the development of the Diagnostic Support System and the Informed Consent Support System by the end of 2021.

CPM-AI system development overview

An infographic accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/83f73696-a87e-4bc4-aebe-8bc216687967

AI “KIBIT” presents a selected range of academic articles by acquiring expert knowledge in specific fields

Currently, a challenge in advancing precision cancer medicine is that as the number of published medical studies and academic reports increases, the options available expand for patient genetic information or abnormal conditions occurring. in cancer cells, treatment regimens and drug choices with incidence of adverse events.

Much is expected of a system that can share information between physicians in a shorter period of time through the use of AI to identify articles with results related to the most appropriate treatment methods and drugs. FRONTEO Healthcare’s CPM-AI system can identify articles containing the same items that experts have confirmed as indicating high quality, and can exclude articles with factors identified by experts as indicating low quality. In many cases, the search for articles of high scientific quality is important for the development of precision cancer medicine. For example, if only articles describing the results of monotherapy should be analyzed or those of combination therapy can also be included, and / or if the genetic information for the analysis should be obtained from cancer cells or from cells normal should be analyzed. These items should be important when researching articles. It has been confirmed that if KIBIT is trained to know whether each of these aspects of research is required or not, it is able to extract articles that meet its objectives.

After learning the most recent medical information selected by experts in a specific field as training data and preselecting research topics, KIBIT can function as a filter that reduces unnecessary data and noise. When the CPM-AI system is developed, it is expected that physicians who have daily contact with cancer patients will be able to use the knowledge of specialists in all fields.

JFCR studied various technologies, including AI developed in Japan, to find a solution that could understand Japanese unique genetic information and protect personal health data. KIBIT got results through its depth of learning and efficient results in a short time with a small amount of data. This, in addition to its cost-effectiveness and the short duration of introduction, was greatly appreciated and made the joint research possible.

By developing and delivering a system that leverages the specialties and respective strengths of JFCR and FRONTEO Healthcare, organizations are working to reduce the cancer death rate in Japan, help prevent recurrence, and reduce cancer death. appropriate allocation of health expenditure.

About FRONTEO, Inc.
FRONTEO, Inc. (“FRONTEO”) (Nasdaq: FTEO) (TSE: 2158) supports behavioral computing-based big data analysis using its technology, “KIBIT”. FRONTEO’s KIBIT technology is driven by FRONTEO’s artificial intelligence based on the knowledge acquired through its litigation support services. KIBIT integrates the tacit knowledge of experts, including their experiences and intuitions, and uses this knowledge for big data analysis. FRONTEO continues to expand its business activities by applying KIBIT to new areas such as healthcare and marketing. FRONTEO was founded in 2003 as a provider of e-discovery services and international litigation assistance. These services include the preservation, investigation and analysis of evidence contained in electronic data, and computer forensic investigation. FRONTEO offers support in e-discovery and litigation by making full use of its “Lit i View” data analysis platform and its predictive coding technology adapted to Asian languages. Company name changed from UBIC, Inc. to FRONTEO, Inc. on July 1, 2016.

For more information on FRONTEO, contact [email protected] or visit http://www.fronteo.com/global/.

About the Japanese Cancer Research Foundation

1. Name of Foundation: Japan Foundation for Cancer Research
2. Date created: April 1908
3. Representative: Takao Kusakari, President
4. Purpose of the establishment: Development of revolutionary cancer treatments and preventive methods through systemic cancer research and the promotion of advanced therapies, and their dissemination through our staff training and exchange operations. international and survey research. In doing so, we will contribute to the well-being of all mankind by defeating cancer.
5. Main organizations: The Cancer Institute Hospital of JFCR, Cancer Institute, Cancer Chemotherapy Center, Cancer Precision Medicine Center
   URL: http://www.jfcr.or.jp/english/

Safe Harbor Declaration
This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “will”, “expect”, “anticipate” “,” The future “,” intentions “,” plans “,” believes “,” estimates “and similar statements. Among other things, the amount of data FRONTEO plans to manage this year, and the potential uses of FRONTEO’s new service in intellectual property litigation, contain forward-looking statements. FRONTEO may also make written or oral forward-looking statements in its reports filed or provided to the United States Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials, and in oral statements made by its leaders. , directors or employees to third parties. Statements that are not historical facts, including statements about the beliefs and expectations of FRONTEO, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including, but not limited to, the following: the objectives and strategies of FRONTEO; FRONTEO’s expansion plans; the expected growth of the data center services market; expectations regarding demand and market acceptance of FRONTEO’s services; FRONTEO’s expectations in terms of maintaining and strengthening its relationships with its customers; FRONTEO’s plans to invest in research and development to improve its solutions and service offerings; and general economic and business conditions in the regions where FRONTEO provides solutions and services. Further information regarding these and other risks is included in the reports of FRONTEO filed or provided to the Securities and Exchange Commission. FRONTEO does not undertake to update any forward-looking statements, except as required by applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and FRONTEO does not undertake to update this information, except as required by applicable law.